deltatrials
Active Not Recruiting PHASE3 Interventional 3-arm NCT03036280

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_ (MissionAD2)

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Sponsor: Biogen

Conditions Alzheimer's Disease
Interventions Elenbecestat (E2609) Placebo
Updated 16 times since 2017 Last updated: Feb 27, 2020 Started: Dec 29, 2016 Primary completion: Nov 21, 2023 Completion: Nov 21, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer's Disease, this trial is ongoing. The trial is conducted by Biogen and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Dec 2017 · 8 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – present · 67 months · monthly snapshot

Change History

16 versions recorded

  1. Jan 2021 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  5. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

▶ Show 11 earlier versions

  1. Mar 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  2. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  3. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  4. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  5. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  6. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  8. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  9. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  10. Apr 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biogen
  • Eisai Co., Ltd.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Albany, United States , Ancona, Italy , Antofagasta, Chile , Atsugi-shi, Japan , Aventura, United States , Ballerup, Denmark , Banska Bystrica, Slovakia , Barcelona, Spain , Baton Rouge, United States and 208 more locations